Breast Cancer clinical trials in Delaware

8 actively recruiting breast cancer trials at 9 sites across Delaware.

Data from ClinicalTrials.gov · last refreshed 2026-07-27

Phase 3 Recruiting Academic/Other

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…

Sponsor: NRG Oncology

NCT ID: NCT05879926

Sites in Delaware:

Bayhealth Hospital Kent Campus — Dover, Delaware
Beebe Medical Center — Lewes, Delaware
Bayhealth Hospital Sussex Campus — Milford, Delaware
Beebe South Coastal Health Campus — Millville, Delaware
Delaware Clinical and Laboratory Physicians PA — Newark, Delaware

View on ClinicalTrials.gov →

Phase 3 Recruiting Network

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…

Sponsor: SWOG Cancer Research Network

NCT ID: NCT03418961

Sites in Delaware:

Bayhealth Hospital Kent Campus — Dover, Delaware
Beebe South Coastal Health Campus — Frankford, Delaware
Beebe Medical Center — Lewes, Delaware
Delaware Clinical and Laboratory Physicians PA — Newark, Delaware
Helen F Graham Cancer Center — Newark, Delaware

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who…

Sponsor: AstraZeneca

NCT ID: NCT05952557

Sites in Delaware:

Research Site — Newark, Delaware

View on ClinicalTrials.gov →

Phase 2, Phase 3 Recruiting Industry

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-pa…

Sponsor: Bristol-Myers Squibb

NCT ID: NCT06926868

Sites in Delaware:

Medical Oncology Hematology Consultants, PA — Newark, Delaware

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT05564377

Sites in Delaware:

Helen F Graham Cancer Center — Newark, Delaware
Medical Oncology Hematology Consultants PA — Newark, Delaware

View on ClinicalTrials.gov →

Phase 1 Recruiting Industry

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…

Sponsor: Tizona Therapeutics, Inc

NCT ID: NCT04485013

Sites in Delaware:

Christiana Care Helen F. Graham Cancer Center — Newark, Delaware

View on ClinicalTrials.gov →

Recruiting Academic/Other

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …

Sponsor: Wake Forest University Health Sciences

NCT ID: NCT06418204

Sites in Delaware:

Beebe South Coastal Health Campus — Millville, Delaware
Helen F Graham Cancer Center — Newark, Delaware
Medical Oncology Hematology Consultants PA — Newark, Delaware
Beebe Health Campus — Rehoboth Beach, Delaware

View on ClinicalTrials.gov →

NA Recruiting Academic/Other

Bundled Cancer Screening and Genetic Services Navigation

The goal of this study is to test bundled familial cancer risk assessment + multicancer (colorectal + breast) vs. single (breast) cancer navigation, using a wait list control for colorectal cancer screening referral and navigation. Among t…

Sponsor: Georgetown University

NCT ID: NCT07228000

Sites in Delaware:

ChristianaCare-Helen F. Graham Cancer Center & Research Institute — Newark, Delaware

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-27